Key Highlights

  • SeaStar Medical (NASDAQ:ICU) changed hands at USD 0.99 on November 12, 2026, a 48.18% loss, across roughly 515,110 shares, leaving a market Capitalization near USD 10.21 million.
  • Third-quarter sales of its QUELIMMUNE device climbed 247% to USD 635,000, but the net loss grew to USD 4.53 million, or USD 1.03 per share.
  • Cash dropped to USD 3.99 million at September 30, 2026 from USD 11.98 million at the close of 2025, while stockholders' Equity contracted to USD 469,000.
  • A shelf registration was filed on October 30, and an early-October Warrant inducement brought in about USD 3.3 million.

Revenue Rises, Losses Rise Faster

SeaStar Medical (NASDAQ:ICU) develops extracorporeal treatments for critically ill patients suffering from severe inflammation and organ failure. Its lead product, QUELIMMUNE, holds United States approval for children with sepsis-associated acute kidney injury requiring dialysis. The company released third-quarter numbers after the bell on November 11, and the share price roughly halved the next day. Revenue increased 247% to USD 635,000 from USD 183,000, with gross Margin topping 90%, a sign of early commercial momentum. Expenses grew faster, though. Research and Development spending almost doubled to USD 3.57 million from USD 1.85 million as the adult NEUTRALIZE-AKI study moved forward, while general and administrative outlays eased to USD 1.59 million. The quarterly net loss expanded to USD 4.53 million from USD 3.47 million, and the nine-month loss hit USD 11.78 million. The company gave neither a full-year forecast nor a runway estimate, so readers have to infer financing needs from the Balance Sheet itself.

The Balance Sheet Points to Further Financing

The likeliest explanation for the sell-off is the balance sheet, though the company linked the decline to no particular item, making that view an interpretation. Cash fell to USD 3.99 million at September 30 from USD 11.98 million at the start of the year, a figure that leaves out about USD 3.3 million of gross proceeds from October warrant exercises. Stockholders' equity declined to USD 469,000 from USD 10.42 million, and shares outstanding increased to around 4.46 million from 3.84 million. With quarterly losses running close to USD 4.5 million, near-term resources appear thin. A shelf registration filed on October 30 lets the company sell securities quickly, and the October inducement repriced warrants to USD 3.866 while issuing new ones at USD 3.616, both well above the present share price. Micro-cap biotechs commonly drop hard once a discounted stock sale looks likely, and fresh shares sold close to today's price would significantly dilute current owners given the small base of about 4.46 million shares.

Clinical Progress Remains the Long-Term Case

Clinical development keeps advancing. NEUTRALIZE-AKI has enrolled 251 of 339 planned adult patients, with enrollment projected to conclude by mid-2027, and the first module of a premarket approval submission has gone in. In October the device received breakthrough designation for adult sepsis, and regulators confirmed that registry results met the pediatric post-approval study requirement, showing day-90 survival of 65.1% compared with a historical benchmark near 47.5%. Trailing diluted losses total USD 3.93 per share, and relative Volume of 1.63 points to above-normal trading. Holders should focus on how new capital will be raised and at what price, whether pediatric sales keep climbing, and whether the adult study wraps up on time.

Where Things Stand

SeaStar Medical (NASDAQ:ICU) slid 48.18% to USD 0.99 on November 12, 2026, after third-quarter results showed fast revenue growth from a small base alongside cash of only USD 3.99 million and equity of USD 469,000. With a shelf registration already on file, the market seems to be pricing in a near-term raise. Study milestones and rising pediatric sales support the long-run thesis, yet near-term funding takes priority.